Top-News
Pharmazeutika USA

Pieris Pharmaceuticals Inc News

Aktie
WKN:  A40A3W ISIN:  US7207952026 US-Symbol:  PIRS
11,00 €
-0,12 €
-1,08%
26.04.24 08:16:28
Handeln Depot/Watchlist
Aktienanzahl *
1,24 Mio.
Marktkapitalisierung *
12,81 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 23.04.2024

Pieris Pharmaceuticals Inc News

27.09.23 - PR Newswire
Thinking about buying stock in Soleno Therapeutics, Lovesac, Pieris Pharmaceuticals, Lithium Americas, or Fisker?
Thinking about buying stock in Soleno Therapeutics, Lovesac, Pieris Pharmaceuticals, Lithium Americas, or Fisker? PR Newswire
08.09.22 - ACCESSWIRE
Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference
BOSTON, MA / ACCESSWIRE / September 8, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through ...
24.08.22 - ACCESSWIRE
Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS
BOSTON, MA / ACCESSWIRE / August 24, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through its ...
04.08.22 - ACCESSWIRE
Pieris Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON THURSDAY, AUGUST 4, 2022 AT 8:00 AM EDT
28.07.22 - ACCESSWIRE
Pieris Pharmaceuticals to Host Second Quarter 2022 Investor Call and Provide Corporate Update on August 4, 2022
BOSTON, MA / ACCESSWIRE / July 28, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through its ...
02.06.22 - ACCESSWIRE
Pieris Pharmaceuticals To Present at Jefferies Healthcare Conference
BOSTON, MA / ACCESSWIRE / June 2, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through its ...
18.05.22 - ACCESSWIRE
Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment Conference
BOSTON, MA / ACCESSWIRE / May 18, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through its ...
11.05.22 - ACCESSWIRE
Pieris Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
Company To Host an Investor Conference Call On Wednesday, May 11, 2022 At 8:00 Am EDT
04.05.22 - ACCESSWIRE
Pieris Pharmaceuticals To Host First Quarter 2022 Investor Call and Provide Corporate Update on May 11, 2022
BOSTON, MA / ACCESSWIRE / May 4, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through its ...
23.04.22 - The Motley Fool
3 riskante Aktien mit großem Potenzial
Viele Menschen wollen nur „sichere“, „ausgereifte“ oder „langweilige“ Aktien besitzen und ignorieren die Chancen auf der riskanten Seite des Aktienuniversums. Auf diese Weise ...
01.03.22 - ACCESSWIRE
Pieris Pharmaceuticals Reports Full-Year 2021 Financial Results and Provides Corporate Update
COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON TUESDAY, MARCH 1, 2022 AT 8:00 AM EST
23.02.22 - ACCESSWIRE
Pieris Pharmaceuticals To Host Full-Year 2021 Investor Call and Provide Corporate Update on March 1, 2022
BOSTON, MA / ACCESSWIRE / February 23, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through ...
14.01.22 - ACCESSWIRE
Pieris Pharmaceuticals Announces Dosing of First Patient in Phase 2 Gastric Cancer Trial of 4–1BB/HER2 Bispecific Cinrebafusp Alfa
BOSTON, MA / ACCESSWIRE / January 14, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through its ...
03.01.22 - ACCESSWIRE
Pieris Pharmaceuticals Announces Successful Completion of Safety Milestone and Initiation of Efficacy Portion of Phase 2a Trial of PRS-060/AZD1402
BOSTON, MA / ACCESSWIRE / January 3, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through its ...
11.11.21 - ACCESSWIRE
Pieris Pharmaceuticals To Participate In Upcoming Investor Conferences
BOSTON, MA / ACCESSWIRE / November 11, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through ...
08.11.21 - ACCESSWIRE
Pieris Pharmaceuticals and Servier Announce Dosing of First Patient in Phase 1/2 Trial of 4-1BB/PD-L1 Bispecific PRS-344/S095012
BOSTON, MA and PARIS, FRANCE / ACCESSWIRE / November 8, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel ...
02.11.21 - ACCESSWIRE
Pieris Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Company To Host an Investor Conference Call on Tuesday, November 2, 2021 at 8:00 AM EDT
26.10.21 - ACCESSWIRE
Pieris Pharmaceuticals To Host Third Quarter 2021 Investor Call and Provide Corporate Update on November 2, 2021
BOSTON, MA / ACCESSWIRE / October 26, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through ...
06.10.21 - ACCESSWIRE
Pieris Pharmaceuticals Announces Appointments of Chief Financial Officer and Chief Business Officer
BOSTON, MA / ACCESSWIRE / October 6, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through its ...
09.09.21 - ACCESSWIRE
Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences
BOSTON, MA / ACCESSWIRE / September 9, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-​stage biotechnology company advancing novel biotherapeutics through ...

Newssuche

Videos

newspaper
07.05.24 +5,69%
Technical Trading: DAX Long kurzfristig
DAX Long Typ: Turbo Open End WKN: NG8K9X Hebel: 26 Laufzeit: OpenEnd Einstieg: Market ... Mehr »